fluoropyrimidines
16 abstracts
Abstract
Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.Org: Oncology Unit Santa Maria delle Croci Hospital, Cardinale G Panico, Azienda Toscana Nord Ovest, University Hospital of Pisa,
Abstract
Frequency of certain germline polymorphisms among ethnicities and adverse drug reaction risk associated with colorectal cancer therapies.Org: OneOme, LLC, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, NewYork-Presbyterian Hospital,
Abstract
Implementing DPYD/UGT1A1 testing to prevent treatment related adverse events (TRAE) in patients with gastrointestinal (GI) cancer: Results of a pragmatic implementation trial.Org: Qral Group, Center for Applied Genomics, Letsgetchecked, Penn Medicine at Lancaster General Health,
Abstract
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.Org: Department of Medical Oncology, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, Center for Cancer Prevention and Early Detection, City of Hope, Phoenix, AZ, Eastern Health & Epworth Healthcare & Eastern Health Clinical School, Monash University, Melbourne, Australia,
Abstract
Effectiveness and safety analysis of serplulimab-based regimens in patients with HER2-negative advanced gastric cancer from a real-world retrospective study.Org: the Fourth Affiliated Hospital of Soochow University,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, UPMC Hillman Cancer Center, NSABP Foundation, Inc. Pathology Lab,
Abstract
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.Org: Maria Sklodowska-Curie National Cancer Research Institute,
Abstract
Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Lake Erie College of Osteopathic Medicine,
Abstract
Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines.Org: Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Saw Swee Hock School of Public Health, National University of Singapore,
Abstract
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,
Abstract
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).Org: University Medical Center Utrecht, Utrecht University, Netherlands Comprehensive Cancer Organisation (IKNL), Erasmus Medical Center, Amsterdam University Medical Centers,
Abstract
Real-world treatment trends and outcomes in elderly patients with metastatic colorectal cancer in the United States.Org: Cleveland Clinic Taussig Cancer Instititute, Huntsman Cancer Institute, University of Utah,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.Org: University of Texas MD Anderson Cancer Center, The University of Pittsburgh, NRG Oncology SDMC, NSABP Foundation, Inc., UMPC Hillman Cancer Center,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
Risk of severe toxicity from topical fluoropyrimidine treatment in patients carrying DPYD variant alleles.Org: University of Michigan, University of Michigan Rogel Comprehensive Cancer Center, University of Michigan College of Pharmacy,
Abstract
Safety and efficacy of trifluridine/tipiracil plus bevacizumab in RAS mutated patients with metastatic colorectal cancer.Org: 2nd Department of Surgery Aretaieion Hospital National and Kapodistrian University of Athens Medical School, Athens, Greece, 2nd Department of Surgery Aretaieion Hospital, Athens, Greece, 2nd Department of Suregery Aretaieion Hospital, Athens, Greece, 2nd Department of Surgery, Areteion Hospital National and Kapodistrian University, Athens, Greece, 2nd Department of Surgery, Areteion Hospital National and Kapodistrian University of Athens, Athens, Greece,